A Smart + Strong Site
Subscribe to:
E-newsletters
POZ magazine
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Treatment News » Top Stories

Most Popular Stories
Marijuana and its CD4 Receptors: A New HIV Treatment Strategy?
Pathway to a Cure: Cancer Drug Helps Purge HIV From Resting Cells
Life Expectancy With HIV Increases Dramatically
Undetectable Viral Load? Not Necessarily in Semen
Engineering CD8 Cells to Kill HIV in Tissues
Pathway to a Cure: Positive Results Continue for Sangamo's CCR5 Gene Therapy
Revised U.S. Guidelines: HIV Treatment is Recommended for All People Living With HIV
What's That Mean?
(just double-click it!)

If you don't understand one of the words in this article, just double-click it. A window will open with a definition from mondofacto's On-line Medical Dictionary. If the double-click feature doesn't work in your browser, you can enter the word below:

Most Popular Lessons
Aging & HIV
The HIV Life Cycle
Shingles
Herpes Simplex Virus
Syphilis & Neurosyphilis
Treatments for Opportunistic Infections (OIs)
What is AIDS & HIV?
More News

Have medical or treatment news about HIV? Send press releases, news tips and other announcements to editors@aidsmeds.com.

Click here for more news


emailprint

January 6, 2009

Not Enough Antibodies to Protect Against Superinfection

Most people’s immune response to HIV isn’t strong enough to protect them from being infected with a second strain of the virus, according to a study published in the December 2008 issue of the Journal of Virology and reported by ScienceDaily.

Scientists believe that up to 5 percent of people with HIV become infected with a second strain of the virus at some time point after their initial infection. This is called superinfection, as opposed to coinfection, which is when a person becomes infected with two strains at the same time. What has been poorly understood, however, are the factors that may put someone at greater risk of superinfection. Some scientists have suggested that it occurs predominantly in people with a weak antibody response to the first infectious strain.

To test this theory, Catherine Blish, MD, at the Fred Hutchinson Cancer Research Center in Seattle and her colleagues examined the immune responses of six women who became superinfected with a second strain of HIV between one and five years after their initial infection. These were compared to a second set of 18 women who had similar risk factors, but who remained infected with a single strain of HIV.

According to test tube research by Blish’s group, the risk factor may be a matter of antibody quantity, not quality. The antibodies against HIV—dubbed broadly “neutralizing antibodies,” or NAbs—found in both groups of women were considered to be potent enough against a second HIV infection. This led to the authors to conclude that many people living with HIV may not produce enough potent antibodies to ward off superinfection.    

Blish and her colleagues warn that scientists working on a preventive HIV vaccine will have to be able to trigger an immune response that is more potent and plentiful than occurs naturally when a person is infected with HIV. They point out that this has been the case with vaccines for other viruses, such as those for hepatitis B and human papillomavirus.

Search: superinfection, antibodies, neutralizing antibodies, NAbs, Catherine Blish, Fed Hutchinson Cancer Center


Scroll down to comment on this story.

Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The AIDSmeds team review all comments before they are posted. Please do not include ":" "@" "<" ">" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

| Posting Rules

Previous Comments:

comments 1 - 1 (of 1 total)    

jjbear, Phoenix, 2009-01-07 09:47:56
did they bother to test for the gene that If you have Both your Imune one a long term survivor and if you have no copie of this genetic trate your a fast progressor?

comments 1 - 1 (of 1 total)    


[Go to top]

Quick Links
AIDSmeds en Español
About HIV and AIDS
Lab Tests
Clinical Trials
HIV Meds
Starting Treatment
Switching Treatment
Drug Resistance
Side Effects
Disclosure
Lipodystrophy
Hepatitis & HIV
Women & Children
Fact Sheets
Treatment News
Community Forums
Blogs
Conference Coverage
Health Services Directory
POZ Magazine


    acousticmat
    Oakland
    California


    Reginaldb06
    los angeles
    California


    tempeststar
    Midtown NYC
    New York


    RayOctober
    Atlanta
    Georgia
Click here to join POZ Personals!
Conference Coverage

19th Conference on Retroviruses and Opportunistic Infections (CROI 2012)
Seattle, Washington
March 5 - 8, 2012


6th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2011)
Rome, Italy
July 17 - 20, 2011


18th Conference on Retroviruses and Opportunistic Infections (CROI 2011)
Boston, MA
February 27 - March 2, 2011


more conference coverage

[ about AIDSmeds | AIDSmeds advisory board | our staff | advertising policy | advertise/contact us]
© 2012 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.